Peptides in three dental nerve cases

A 2026 case series described three people whose altered lower-lip and chin sensation improved after a four-week multimodal intervention for inferior alveolar nerve injury. Every patient received ARA-290, BPC-157, TB-500, a corticosteroid, and a local anaesthetic together. There was no untreated comparison group, no blinding, and no standardised sensory testing. The report cannot show that any peptide caused the recoveries^[2].

All three injuries followed dental procedures

The inferior alveolar nerve runs through the lower jaw and supplies sensation to the lower lip and chin. Injury can follow implant work or extraction near the mandibular canal. The three patients in this report were 38, 85, and 48 years old. Their symptoms followed implant placement, removal of a failed implant, or tooth extraction with bone grafting^[2].

Imaging suggested different injury patterns. In the first two cases, the implant or osteotomy site lay about 2 mm from the nerve canal without visible penetration. The authors considered compression or local inflammation plausible. In the third case, pre-existing tooth pathology extended into the canal before extraction, which suggested a more direct injury pattern^[2]. None of the cases documented complete nerve transection.

The intervention bundled several active agents

Each patient received weekly local injections for four weeks. The mixture contained ARA-290, BPC-157, TB-500, dexamethasone, bupivacaine, and epinephrine^[2]. Dexamethasone can reduce inflammation, while bupivacaine blocks local nerve signalling. With all components administered together, the clinical course cannot be assigned to one peptide or even to the peptide portion of the mixture.

The paper gives the experimental amounts and injection approach, but reproducing that protocol would be unsafe and misleading. It has not been validated in a controlled trial. A case report can document what clinicians tried; it cannot define an effective dose or an appropriate patient. Nor can it establish a standard dental treatment. The authors describe the peptide agents as investigational and identify unresolved questions about safety and delivery. Long-term outcomes also remain uncertain.

Sensation improved during follow-up

The first patient began with a broad right-sided sensory deficit after implant placement. Four weeks later, the report describes marked improvement with a residual area of reduced sensation measuring about 3 mm below the lower lip. The second patient also improved over four weeks, with a residual area of about 2 mm at the side of the chin. No treatment-associated complications were reported in either case^[2].

The third patient had persistent numbness after extraction and grafting. The authors report an approximately 95% subjective reduction in numbness by the end of treatment, later bone healing, and implant placement after six months. No treatment complication was reported^[2]. The 95% figure came from subjective symptom assessment rather than a prospectively validated sensory instrument.

The design cannot establish efficacy

Inferior alveolar nerve symptoms can improve spontaneously, especially when the injury involves compression or temporary conduction block rather than complete transection. The report had no untreated group to estimate that natural recovery. It also lacked random allocation and blinded assessment. Placebo effects and regression to the mean are plausible explanations for some of the change. Variation in injury severity and the non-peptide drugs add further uncertainty^[2].

Outcome measurement adds another limit. The authors relied mainly on routine examination and patient reports, supported by photographs. They did not prospectively collect electrophysiology or quantitative sensory testing. Thermal discrimination, two-point discrimination, pin-prick testing, and validated patient-reported outcome measures were also absent. Follow-up duration differed among patients^[2]. The apparent magnitude of recovery therefore cannot be compared cleanly with other treatment series.

The biological rationale remains preclinical

The review portion discusses pathways involved in peripheral nerve repair, including inflammation, blood-vessel signalling, extracellular-matrix remodelling, Schwann-cell activity, and axonal regrowth. It links ARA-290, BPC-157, and thymosin beta-4 derivatives to those pathways through experimental literature. None of those mechanisms was measured in these three patients^[2]. A plausible pathway can motivate a trial, but it does not prove that the pathway changed in a treated person.

The paper uses TB-500 in the intervention, while the broader literature often discusses full-length thymosin beta-4 or derivatives. Those names do not always identify the same molecule. Our TB-500 evidence page explains that identity problem and the lack of established systemic injury-recovery trials. This case series does not close that gap.

What a controlled study would need

A useful next study would enrol patients with clearly classified nerve injuries and use a comparison group receiving contemporary standard management. It would prespecify objective sensory measures, consistent follow-up times, adverse-event collection, and a primary endpoint. Separate study arms would be needed to distinguish the peptide combination from dexamethasone, local anaesthetic, and spontaneous healing^[2].

No treatment-associated adverse events were documented in the three cases, but three observations over short and inconsistent follow-up cannot define safety. The intervention combined six agents, which also makes attribution difficult if a later study finds benefit or harm. A controlled protocol would need prespecified safety outcomes and enough participants to detect more than common immediate reactions^[2].

PubMed classifies the article as a case report and journal article in Frontiers in Oral Health, published in 2026 with DOI 10.3389/froh.2026.1907109^[1]. The authors call the observations hypothesis-generating. That is the appropriate boundary: three recoveries occurred during a multi-agent intervention, but the report cannot identify why they occurred or establish a peptide treatment for dental nerve injury.